Honoring excellence: Werner Seeger and Mareike Lehmann receive prestigious awards At this year’s American Thoracic Society (ATS) Congress in San Diego, Prof. Werner Seeger, Chairman of the Board and Spokesman of the Deutsches Zentrum für Lungenforschung (DZL), was honored with the esteemed Robert F. Grover Award. This accolade recognizes his lifetime contributions to #pulmonary #hypertension (PH) research. The award, presented annually for significant advancements in understanding the effects of hypoxia and high altitude on pulmonary circulation, celebrates Prof. Seeger’s remarkable impact in the field. Additionally, Prof. Mareike Lehmann from the Institute of Lung Research at Philipps-Universität Marburg was awarded the Carol Basbaum Award. This prestigious award acknowledges outstanding young scientists for their exceptional achievements, mentorship, and leadership in cell and molecular biology of the #respiratory tract. Congratulations to both Prof. Seeger and Prof. Lehmann for their exceptional contributions and well-deserved recognition! Read more on the DZL website by following the link below: https://lnkd.in/ebTgwdYQ #DZL #DZG #PulmonaryResearch #LungDisease #Science #ATS2024 #PulmonaryHypertension #RobertFGroverAward #CarolBasbaumAward #DZL #ResearchExcellence #MedicalResearch #PulmonaryMedicine #LeadershipInScience
Deutsches Zentrum für Lungenforschung (DZL)
Forschungsdienstleistungen
German Center for Lung Research
Info
Das Deutsche Zentrum für Lungenforschung (DZL) wurde im Herbst 2011 als eines von sechs Deutschen Zentren der Gesundheitsforschung (DZG) gegründet. Das DZL wird durch das Bundesministerium für Bildung und Forschung (BMBF) und die Bundesländer, in denen die jeweiligen Standortverbünde angesiedelt sind, gefördert. Im DZL arbeiten derzeit über 240 Projektleiter:innen und ihre Arbeitsgruppen zusammen an der Bekämpfung von Lungenerkrankungen durch translationale Forschung. Dabei kooperieren 29 führende deutsche Forschungseinrichtungen an fünf Standorten. Ziel der translationalen Forschung im DZL ist es, die Ursachen von Lungenerkrankungen besser zu verstehen und Forschungsergebnisse aus dem Labor schneller in die Praxis (engl. „bench-to-bed-side“) zu überführen. Im DZL arbeiten exzellente universitäre und außeruniversitäre Einrichtungen für das Wohl der Patient:innen eng zusammen, um zügig neue Ansätze für die Prävention, Diagnose und Therapie von Lungenerkrankungen zu entwickeln. Die Weltgesundheitsorganisation (WHO) zählt vier Lungenerkrankungen zu den zehn häufigsten Todesursachen und jeder fünfte Todesfall wird durch eine Lungenerkrankung oder durch Folgen davon verursacht. Bis heute gibt es für die meisten Atemwegserkrankungen nur Therapien, die symptomatische Erleichterungen bieten, jedoch keine Heilung. Daher ist es umso wichtiger, durch Forschung zu Ursachen und Krankheitsmechanismen neue Ansätze und Optionen für Prävention, Diagnose und Therapie zu entwickeln.
- Website
-
https://dzl.de/en/
Externer Link zu Deutsches Zentrum für Lungenforschung (DZL)
- Branche
- Forschungsdienstleistungen
- Größe
- 501–1.000 Beschäftigte
- Hauptsitz
- Giessen
- Art
- Nonprofit
- Gegründet
- 2011
- Spezialgebiete
- Lung Cancer, Chronic Obstructive Pulmonary Disease, Asthma and Allergy, Cystic Fibrosis, Pneumonia and Acute Lung Injury, Diffuse Parenchymal Lung Disease, Pulmonary Hypertension und End-Stage Lung Disease
Orte
Beschäftigte von Deutsches Zentrum für Lungenforschung (DZL)
-
Peter Dorfmüller
Oberarzt / Consultant pathologist at Universitätsklinikum Gießen und Marburg GmbH, Pathology Department
-
Doreen Franke
Program Director - Career Development - Institute of Lung Health and Immunity at Helmholtz Munich
-
Baktybek Kojonazarov
Head of the Imaging Platform at Institute for Lung Health
-
Nestor I. Zaragoza -Jimenez
Mixed methods research scientist, data analyst & neuroscientist.
Updates
-
Leadership Transition at DZL Site BREATH Following the unexpected passing of Prof. Dr. Tobias Welte, we are pleased to announce that Prof. Dr. Gesine Hansen has been appointed as the new Director of the Deutsches Zentrum für Lungenforschung (DZL) site BREATH. Prof. Dr. Hansen, Medical Director of Pediatric Pneumology, Allergology, and Neonatology at Hannover Medical School, has officially joined the DZL Board of Directors as of early June, as announced at the 12th DZL Annual Meeting in Bad Nauheim. She brings a wealth of experience to her new role, with significant contributions to clinical practice, research, and education. Her roles include: Spokesperson for the Collaborative Research Center 587 (DFG) Spokesperson for TITUS Research College (Else Kröner-Fresenius Foundation) Deputy Spokesperson for the RESIST Excellence Cluster President of the Society for Pediatric Pneumology Senator and Research Commission member at Hannover Medical School Board member of the National Genome Research Network (NGFN) Elected member of the National Academy of Sciences Her research focuses on the immunological mechanisms of allergies and tolerance, aiming to develop preventive and therapeutic strategies for allergic diseases. We look forward to her leadership and continued contributions to advancing research and patient care. #DZL #DZG #PulmonaryResearch #LungDisease #Science #Leadership #DZL #PediatricPneumology #Research #Allergies #Immunology #Healthcare #Innovation
Prof. Dr. Gesine Hansen Appointed New Director of the DZL Site BREATH
https://dzl.de/en/
-
DGP Research Award 2024: DZL Researcher Unveils Key Molecule in COPD Defense Congratulations to Dr. Cheng-Yu Wu (Daniel) from Justus Liebig University Giessen for winning the Pneumology Research Prize 2024! His groundbreaking identification of the molecule #CEACAM6, which regulates antioxidant defense at the protein level, offers promising new directions for diagnosing and treating Chronic Obstructive Pulmonary Disease (#COPD). Dr. Wu analyzed biological samples from COPD patients, comparing them with healthy controls to uncover endogenous mechanisms influencing the disease's progression. His novel in vitro model for cigarette smoke-resistant cells allowed him to identify CEACAM6 as crucial for the body's resistance to COPD. Potential clinical applications of his findings include developing a biomarker for early detection and creating therapies that enhance antioxidant defenses by targeting CEACAM6. These insights could also benefit treatments for other diseases caused by oxidative stress. The prize, awarded at the DGP Annual Congress in Mannheim, comes with a €10,000 endowment. Read more on the DZL website by following the link below: https://lnkd.in/eKnsanwX #DZL #DZG #PulmonaryResearch #LungDisease #Science #COPD #MedicalResearch #DGPResearchAward #CEACAM6 #HelmholtzZentrumMünchen #LungHealth #Innovation #DZL #AntioxidantDefense #Biomarkers #TherapeuticDevelopment
DGP Research Award 2024: DZL Researcher Discovers Endogenous Molecule Impacting COPD Defense
https://dzl.de/en/
-
DGP Research Award 2024: Recognizing DZL Scientists' Study on Pulmonary Fibrosis! Congratulations to Janine Gote-Schniering and Niklas Lang from the Helmholtz Munich Institute of Lung Health and Immunity for winning the #Pneumology Research Prize 2024! Their innovative work on pulmonary fibrosis using the Precision-Cut Lung Slice (#PCLS) model has been recognized as the best basic scientific research by the German Respiratory Society (Deutsche Gesellschaft für Pneumologie und Beatmungsmedizin e.V., #DGP). Using the advanced hPCLS model, they successfully simulated fibrotic processes in healthy human #lung tissue and analyzed these mechanisms at the single-cell level with state-of-the-art #genomics and #AI-assisted analyses. This model provides a more accurate depiction of the lung's complexity, enabling the study of cellular changes in the early stages of pulmonary fibrosis and testing new antifibrotic medications directly in human tissue. This significant research holds promise for developing new therapies for pulmonary fibrosis, a disease currently lacking effective treatment options. The prize, awarded at the DGP Annual Congress in Mannheim, includes a €10,000 endowment. Read more on the DZL website by following the link below: https://lnkd.in/ew2kAuH7 #DZL #DZG #PulmonaryResearch #LungDisease #Science #PulmonaryFibrosis #MedicalResearch #DGPResearchAward #PrecisionCutLungSlice #HelmholtzZentrumMünchen #LungHealth #Innovation #AI #SingleCellGenomics #DZL
DGP Research Award 2024: DZL Study on Pulmonary Fibrosis Recognized
https://dzl.de/en/
-
Breakthrough in Protecting Lung Transplant Patients from COVID-19 Researchers at the Deutsches Zentrum für Lungenforschung (DZL) sites in Munich and Hanover have made a significant discovery: preventive treatment with specific monoclonal antibodies can reduce the risk of SARS-CoV-2 infection in lung transplant recipients. This finding is crucial as these patients are at increased risk of severe #COVID19 and often do not respond effectively to #vaccinations. The study analyzed 1,438 #lung #transplant patients, 29% of whom received pre-exposure prophylaxis (#PrEP) with the monoclonal antibodies #Tixagevimab and #Cilgavimab. These #antibodies are derived from individuals previously infected with the coronavirus and neutralize SARS-CoV-2 effectively. Patients received PrEP based on their doctor's discretion, particularly if they had additional health conditions, were older, or did not produce sufficient antibodies after vaccination. Despite being at higher risk, the PrEP group experienced COVID-19 outcomes similar to those not receiving PrEP. This suggests that PrEP not only prevents infection but may also mitigate the severity of the disease. Read more on the DZL website by following the link below: https://lnkd.in/enTWQRzc #DZL #DZG #PulmonaryResearch #LungDisease #Science #COVID19 #LungTransplant #MedicalResearch #MonoclonalAntibodies #SARSCoV2 #DZL #HealthcareInnovation #PatientSafety #PrEP #Tixagevimab #Cilgavimab
Protection against SARS-CoV-2 infection after lung transplantation
https://dzl.de/en/
-
New Insights into Pulmonary Fibrosis In a significant breakthrough, researchers led by Gerald Burgstaller and Herbert Schiller from Helmholtz Munich, the German Center for Lung Research (DZL), and LMU Klinikum München have uncovered how various types of #fibroblasts in the lungs activate and change during injury and repair. Their study highlights the crucial role of Secreted Frizzled Related Protein 1 (SFRP1) in modulating the effects of transforming growth factor beta (TGFβ) signaling. #Pulmonary #fibrosis, a currently incurable disease, lacks effective treatments to halt or reverse its progression. Understanding the cellular and molecular mechanisms behind this disease is vital for developing targeted therapies. The team used advanced techniques like genetic lineage tracing, spatial transcriptomics, and time-resolved single-cell transcriptomics to study the early stages of fibrosis. Their findings reveal a new model for the spatiotemporal evolution of distinct fibroblast states post-injury, identifying an injury-activated transitional cell state that later differentiates into invasive myofibroblasts through TGFβ-mediated signaling. Importantly, they demonstrate how SFRP1 influences this process, offering a novel pathway for potential therapeutic targets against fibrosis. Read more on the DZL website by following the link below: https://lnkd.in/d9T4q5H7 #DZL #DZG #PulmonaryResearch #LungDisease #Science #PulmonaryFibrosis #MedicalResearch #LungHealth #Fibroblasts #DZL #HelmholtzMunich #LMU #TGFβ #SFRP1
Diversity Matters: Fibroblast Heterogeneity in Pulmonary Fibrosis
https://dzl.de/en/
-
Three German Clinician-Scientists Named First-Ever Fellows of the American Thoracic Society For the first time, three distinguished clinician-scientists from Germany have been elected as Fellows of the prestigious American Thoracic Society (ATS). This landmark achievement underscores the high level of excellence and dedication within the German research community and highlights Germany's leading role in global lung research. The three researchers, all members of the DZL, are: - Dr. Susanne Herold, University Hospital Giessen and Marburg GmbH (UKGM) - Dr. Wolfgang Kübler, Charité - University Medicine Berlin - Dr. Jonas Schupp, Hannover Medical School (MHH) Founded in 1905, the American Thoracic Society is the world's leading #medical #society dedicated to accelerating progress in global #respiratory #health through multidisciplinary collaboration, education, and advocacy. The core activities of the Society's more than 16,000 members focus on pioneering scientific discovery, advancing professional development, impacting global health, and transforming patient care. Key areas of focus include developing #clinical #guidelines, hosting the annual International #Conference, publishing four peer-reviewed journals, advocating for improved respiratory health worldwide, and providing a variety of patient #education and professional development resources. #DZL #DZG #MedicalExcellence #LungResearch #GermanResearchers #AmericanThoracicSociety #GlobalHealth #RespiratoryHealth #ScientificDiscovery #HealthcareInnovation #DZL #ClinicianScientists
Erstmals drei deutsche Clinician-Scientists als Fellow der American Thoracic Society ausgewählt
https://dzl.de
-
Patient Forum at the Lung Congress: Patients Ask, Experts Answer A standout event at the German Respiratory Society (Deutsche Gesellschaft für Pneumologie und Beatmungsmedizin e.V.) Congress in March was the Lung Patient Forum. Around 200 people with lung disease attended and took the opportunity to put their questions to leading #experts in #lung #research. The overwhelmingly positive feedback underscored the popularity of this format, which was organized in cooperation with the #Lung #Information #Service and the German Lung Congress. The forum began with brief updates from the specialists: - Prof. Dr. med. Monika Gappa discussed factors influencing lung health throughout life and recommended measures to maintain healthy lungs. - Prof. Dr. med. @Michael Kreuter from the DZL introduced the diversity of #interstitial lung diseases and the importance of detailed diagnosis for effective treatment. - Prof. Dr. med. Christiane Lex presented key facts about #asthma in children and adolescents, emphasizing unique aspects of diagnosis and therapy. - Prof. Dr. med. Marek Lommatzsch reviewed the evolution of #asthma treatment in adults, from constant acute therapy in the 20th century to personalized approaches in the 21st century. - Dr. med. Nicole Maison, a DZL researcher, highlighted new diagnostic and therapeutic possibilities along with current research on #allergies in children and adolescents. - Prof. Dr. med. Klaus F. Rabe, a DZL researcher and board member, examined the factors influencing the onset and progression of #COPD, alongside current therapy recommendations. - Univ.-Prof. Dr. med. Gernot Rohde, another DZL researcher, provided an update on #respiratory #infections, covering risk factors, diagnostics, treatment, and prevention. - Dr. med. Hubert Schädler discussed the mechanisms of cough development and potential causes of #chronic #cough. - Prof. Dr. med. Wolfgang Schütte addressed current topics in #lung #cancer, spanning prevention, various treatment methods, and new concepts for metastatic stages. This informative event underscored the crucial role of patient engagement in advancing lung health awareness and education. #DZL #LungCongress2024 #LungHealth #PatientForum #RespiratoryHealth #LungDiseaseAwareness #AsthmaAwareness #COPD #LungCancerResearch #PulmonaryMedicine #HealthEducation #PatientEngagement #MedicalResearch #DZL #DeutscherLungentag #LungInformationService #Lungeninformationsdienst
Patient Forum at the Lung Congress: Patients Ask, Experts Answer
https://dzl.de/en/
-
New SYNERGIE Magazine on the "Exposome" Published The latest issue of the DZG magazine, #SYNERGIE, has been released! This year's first issue focuses on the "exposome" — all external factors affecting the body. Although the term "exposome" is relatively new, the impact of environmental influences on human health has become a major research area. Researchers are examining how short-term and long-term exposures affect the body's regulatory systems, with changes in #epigenetic markers that can alter #gene #expression over time. The cover story of this SYNERGIE issue highlights the importance of the #exposome in all diseases studied by the German Centres for Health Research (DZG). This theme is further explored in a foreword by Prof. Wolfgang Wick, Chairman of the German Council of Science and Humanities. Highlight on DZL’s Contribution: "What Does the Breath Tell Us?" SYNERGIE aims to present the latest DZG research in an accessible manner for science and medicine enthusiasts. This issue emphasizes translational projects. The DZL contribution discusses measuring "Volatile Organic Compounds" (#VOCs) in exhaled air and the potential for diagnosing diseases or specific phenotypes from these compounds. Dr. Nicole Maison (CPC-M) and Dr. Olaf Holz (BREATH) share findings from the #ALLIANCE asthma register. The issue also features young scientist Dr. Carola Voss from Munich. How to Read SYNERGIE You can read the new #SYNERGIE articles on the website by following this link: https://dzg-magazin.de or via the e-reader: https://lnkd.in/e98i5kCR For a tactile experience, you can also subscribe to the #print edition: https://lnkd.in/dqYcJ7At #DZL #SYNERGIEmagazine #Exposome #DZG #HealthResearch #TranslationalScience #Epigenetics #VOCs #AsthmaResearch #ScientificPublication #HealthInfluences #ScienceCommunication #EnvironmentalHealth #GeneExpression #ResearchHighlights
New SYNERGIE magazine about „Exposome“ published
https://dzl.de/en/
-
National Strategy for Gene and Cell-Based Therapies The "National Strategy for Gene- and Cell-Based Therapies" was presented to the German Federal Minister of Research, Bettina Stark-Watzinger, on June 12. The aim is to improve patient care and strengthen Germany's position in the field of gene and cell-based therapies (GCT). In fall 2022, the Federal Ministry of Education and Research (BMBF) commissioned the Berlin Institute of Health at Charité (BIH) to coordinate the creation of a national strategy for gene- and cell-based therapies. Around 150 experts from various stakeholder groups drew up the paper and developed a roadmap for improving healthcare and strengthening Germany as a location for gene- and cell-based therapies. Several experts from the German Centers for Health Research (DZG), to which the Deutsches Zentrum für Lungenforschung (DZL) belongs, were also represented in the various working groups. #Gene and #cell-based #therapies offer innovative treatment options that directly target the genetic causes of diseases. This is particularly promising for patients with severe and rare diseases. The strategy includes eight lines of action: 1. stakeholder networking and support 2. training and capacity building 3. technology transfer 4. standards and regulatory frameworks 5. building quality and capacity in GMP manufacturing 6. research and development 7. market approval and transition to supply 8. interaction with society The strategy will be implemented in a national network, supported by measures such as a National Network Office for Gene and Cell Therapies and the GeneNovate entrepreneurship program. 48 million euros are available for the years 2023-2026 to implement these measures. Read more about the "National Strategy for Gene and Cell-Based Therapies" on the DZL website: https://lnkd.in/eyMXhb5X
National Strategy for Gene and Cell Therapies opens up new perspectives for patients
https://dzl.de/en/